Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.02.2024 | Case report

Avibactam/ceftazidime/aztreonam

Drug resistance and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mercadante S, et al. The Use of Cefiderocol as Salvage Therapy in an Infant Receiving ECMO and Continuous Renal Replacement Therapy. Antibiotics 13: No. 1, Jan 2024. Available from: URL: https://dx.doi.org/10.3390/antibiotics13010037 Mercadante S, et al. The Use of Cefiderocol as Salvage Therapy in an Infant Receiving ECMO and Continuous Renal Replacement Therapy. Antibiotics 13: No. 1, Jan 2024. Available from: URL: https://dx.doi.org/10.3390/antibiotics13010037
Metadaten
Titel
Avibactam/ceftazidime/aztreonam
Drug resistance and lack of efficacy
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53492-0

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Cotrimoxazole

Case report

Camrelizumab